Back to top

immuno-therapy: Archive

Zacks Equity Research

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.

SRPTNegative Net Change ARQTNegative Net Change CGEMPositive Net Change AVTXNegative Net Change

Zacks Equity Research

IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why

IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.

SNYNegative Net Change PBYIPositive Net Change ADMANegative Net Change IGMSNegative Net Change